[1]
L. Hanna, R. O’Dwyer, Z. Hamilou, K. Noonan, S. Doucette, and S. S. Sridhar, “Expert opinion on the management of anemia in prostate cancer patients receiving PARP inhibitors”, CUAJ, vol. 19, no. 12, pp. 422–31, Dec. 2025.